In another sign of the the growing prominence of generics at the US FDA, the Center for Drug Evaluation and Research's formal dispute resolution program is moving out of the Office of New Drugs.
Most of the appeals now reviewed involve generics, Center for Drug Evaluation and Research Director Janet Woodcock said in the...